RedHill Biopharma (RDHL) Payables (2011 - 2025)

RedHill Biopharma (RDHL) has reported Payables for 15 consecutive years, with $731000.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Payables fell 37.41% year-over-year to $731000.0 in Q4 2025; TTM through Dec 2025 was $731000.0, a 37.41% decrease from a year earlier, with the FY2025 full-year figure at $731000.0, down 37.41% from the prior year.
• Payables was $731000.0 for Q4 2025 at RedHill Biopharma, down from $835000.0 in the prior quarter.
• Over five years, Payables peaked at $119.4 million in Q4 2022 and troughed at $731000.0 in Q4 2025.
• A 5-year average of $18.8 million and a median of $4.8 million in 2022 frame the typical range for Payables.
• Across the five-year window, Payables surged 924.06% in 2022 and slumped 97.26% in 2023, its largest moves.
• Over 5 years, Payables stood at $11.7 million in 2021, then surged by 924.06% to $119.4 million in 2022, then tumbled by 97.26% to $3.3 million in 2023, then slumped by 64.37% to $1.2 million in 2024, then sank by 37.41% to $731000.0 in 2025.
• The last three Payables figures came in at $731000.0 (Q4 2025), $835000.0 (Q2 2025), and $1.2 million (Q4 2024), per Business Quant data.